Vironexis Therapy Induced Leukemia Remissions
The experimental VNX-101 treatment triggered durable responses in relapsed patients during early-stage testing.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Should medical research prioritize one-time, durable treatments over traditional, repeated long-term therapies?
Three patients with relapsed or refractory acute lymphoblastic leukemia achieved MRD-negative complete responses following a single administration of the experimental drug VNX-101. These results from the SENTRY-CD19 study represent early-stage research data.
Why it matters
The therapy aims to transform the liver into a biofactory for CD19/CD3 proteins, potentially providing a durable one-time alternative to repeated infusions for blood cancer patients. This approach seeks to overcome the logistical and durability challenges of continuous treatment cycles.
In the SENTRY-CD19 trial, the first patient remained MRD-negative through day 260, with researchers observing sustained detection of T-cell-engaging proteins for nine months. Clinical responses were confirmed via PET imaging and clonoSEQ, a sequencing-based method for detecting minimal residual disease.
The players
Vironexis
A biotechnology company focused on gene therapy platforms designed to turn the liver into a persistent protein production biofactory.
Kevin Sharer
The newly appointed Chairman of the Board of Directors at Vironexis.
Dr. James Allison
A Nobel laureate and immunologist who joined the Vironexis Scientific Advisory Board.
The details
VNX-101 uses a viral vector to turn the liver into a site for continuous production of CD19/CD3 protein, which recruits the immune system to target cancer cells. During the administration, clinicians observed immune-mediated events such as cytokine release syndrome, a systemic inflammatory response, and immune effector cell-associated neurotoxicity syndrome, which were successfully resolved. The study currently excludes patients who have pre-existing anti-AAV antibodies, a common immune response to adeno-associated virus vectors used in gene delivery.
Timeline
Sept. 21, 2026: Vironexis announced the clinical results and new board appointments.
28 days post-administration: A patient with extramedullary disease achieved a complete response.
Day 260: The first patient remained MRD-negative.
Coming weeks: SENTRY-CD19 clinical sites in South Korea are expected to activate.
The Tech Race
This development marks a milestone for the SENTRY-CD19 study as it expands from domestic sites to international expansion in South Korea. The work sits alongside broader industry efforts to replace traditional serial protein infusions with durable, one-time genetic interventions.
The therapy is currently limited to patients in the SENTRY-CD19 trial who are anti-AAV antibody-naïve, meaning they lack preexisting immunity that would neutralize the delivery vector. As research progresses, Vironexis intends to prioritize this cohort, though no commercial availability or pricing has been announced.
The takeaway
Vironexis has successfully demonstrated that VNX-101 can induce complete remissions in a small cohort of leukemia patients. Stakeholders should watch for the upcoming activation of South Korean clinical sites and any subsequent long-term safety data reports from the SENTRY-CD19 study.
What happens next
The SENTRY-CD19 study is scheduled to activate clinical sites in South Korea in the coming weeks.
Further reading
For more on the current landscape of gene-based cancer therapeutics, visit our Biotech section.
More information
Review the latest study parameters via the clinical trial listing information.
Live Poll
Should medical research prioritize one-time, durable treatments over traditional, repeated long-term therapies?
